A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 36
Summary
- Conditions
- Alcoholic Hepatitis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03432260
- Collaborators
- CTI Clinical Trial and Consulting Services
- Investigators
- Study Director: Robert Gordon, MD CTI Clinical Trial and Consulting Services
Get Well Soon